News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,349 Results
Type
Article (14090)
Company Profile (108)
Press Release (252151)
Section
Business (88585)
Career Advice (469)
Deals (15459)
Drug Delivery (64)
Drug Development (37566)
Employer Resources (50)
FDA (6412)
Job Trends (6338)
News (151911)
Policy (14211)
Tag
Academia (449)
Alliances (23353)
Alzheimer's disease (380)
Approvals (6424)
Artificial intelligence (74)
Bankruptcy (144)
Best Places to Work (4505)
Breast cancer (67)
Cancer (500)
Cardiovascular disease (46)
Career advice (410)
Cell therapy (71)
Clinical research (31435)
Collaboration (230)
Compensation (99)
COVID-19 (765)
C-suite (74)
Data (474)
Diabetes (65)
Diagnostics (1276)
Drug discovery (46)
Drug pricing (59)
Earnings (31962)
Events (37720)
Executive appointments (255)
FDA (6683)
Funding (152)
Gene therapy (72)
GLP-1 (320)
Government (1305)
Healthcare (3634)
Infectious disease (787)
Inflammatory bowel disease (50)
Interviews (59)
IPO (5927)
Job creations (2055)
Job search strategy (376)
Layoffs (175)
Legal (3427)
Lung cancer (66)
Lymphoma (74)
Manufacturing (113)
Medical device (1330)
Medtech (1332)
Mergers & acquisitions (9633)
Metabolic disorders (199)
Neuroscience (502)
NextGen: Class of 2025 (1597)
Non-profit (608)
Northern California (558)
Obesity (118)
Opinion (115)
Patents (70)
People (28702)
Pharmaceutical (67)
Phase I (8338)
Phase II (13339)
Phase III (11836)
Pipeline (238)
Policy (47)
Postmarket research (1408)
Preclinical (3278)
Radiopharmaceuticals (117)
Rare diseases (115)
Real estate (2640)
Regulatory (10098)
Research institute (584)
Resumes & cover letters (56)
Southern California (540)
Startups (1634)
United States (5402)
Vaccines (125)
Weight loss (86)
Date
Today (15)
Last 7 days (250)
Last 30 days (761)
Last 365 days (12680)
2025 (587)
2024 (12810)
2023 (14597)
2022 (20033)
2021 (20484)
2020 (19365)
2019 (15202)
2018 (11896)
2017 (14117)
2016 (13302)
2015 (15654)
2014 (12555)
2013 (10675)
2012 (11458)
2011 (12028)
2010 (10956)
Location
Africa (313)
Asia (20235)
Australia (2628)
California (1296)
Canada (730)
China (173)
Colorado (54)
Connecticut (57)
Europe (39718)
Florida (210)
Illinois (151)
Indiana (103)
Japan (60)
Kansas (54)
Maryland (194)
Massachusetts (1114)
Minnesota (72)
New Jersey (531)
New York (364)
North Carolina (321)
Northern California (558)
Pennsylvania (340)
South America (503)
Southern California (540)
Texas (169)
Virginia (49)
Washington State (93)
266,349 Results for "diffusion pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
CAR T Cell Therapy Breyanzi® (lisocabtagene maraleucel) Approved for Second-Line Relapsed or Refractory Diffuse Large B-cell Lymphoma
January 14, 2025
·
5 min read
Deals
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) today announced that its stockholders have voted to approve all proposals at a special meeting of stockholders held earlier today, including the issuance of Diffusion Common Stock in the pending merger with EIP Pharma Inc. (“EIP”), and a reverse stock split of outstanding Diffusion Common Stock (the “Reverse Split”).
August 15, 2023
·
6 min read
Pharm Country
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Regeneron Pharmaceuticals, Inc. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
June 28, 2024
·
10 min read
Press Releases
The Future of Diffuse Large B-Cell Lymphoma (DLBCL) Treatment: Insights from Global Research
November 18, 2024
·
3 min read
Press Releases
World’s First Drug Candidate developed by Organoid and AI Doses First Patient in Phase 1 Study for first Diffusive Gastric Cancer Targeted Therapy
January 14, 2025
·
3 min read
Press Releases
ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma
December 31, 2024
·
7 min read
Press Releases
FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
December 5, 2024
·
10 min read
Press Releases
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
December 30, 2024
·
4 min read
Press Releases
FDA Accepts Supplemental Biologics License Application for Genentech’s Columvi Combination for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
December 5, 2024
·
16 min read
InnoCare Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China
InnoCare Pharma announced today that China National Medical Products Administration (NMPA) has accepted and granted priority review to a biologics license application (BLA) for tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
June 20, 2024
·
4 min read
1 of 26,635
Next
